证券代码：300453 证券简称：三鑫医疗 江西三鑫医疗科技股份有限公司 投资者关系活动记录表 编号：20230811 | --- | --- | --- | |----------------|--------------|--------------------------------------| | | 特定对象调研 | 分析师会议 | | | □媒体采访 | 业绩说明会 | | 投资者关系活动 | □新闻发布会 | 路演活动 | | 类别 | 现场参观 | 其他 2023 年半年度业绩交流会（电话会 | 议） 东吴证券 华安证券 国元证券 申万菱信 聚鸣投资 永赢基金 参与单位名称 安信证券 华宝基金 汇丰晋信 浦银安盛 鹏华基金 万家基金 信达澳亚 时间 2023年8月10日-2023年8月11日 地点 电话会议 上市公司接待 董事、副总裁、董事会秘书 刘明 人员姓名 证券事务代表 周文燕 一、简要介绍公司主营业务等基本情况 公司董事、副总裁、董事会秘书刘明简要介绍了公司 2023 年上半 年经营情况。 2023 年上半年，公司实现营业收入 58,174.55 万元，较上年同期下 降 11.88% ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2023-051 江西三鑫医疗科技股份有限公司 关于获得血液透析浓缩液注册证的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"）于近日取得了国家药品 监督管理局颁发的《医疗器械注册证》，现将主要情况公告如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期 | 注册 分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | | | | 2023年8月9日 | | 适用于急、慢性肾 | | 1 | 血液透析浓 | 国械注准 | 至 | Ⅲ类 | 功能衰竭患者的血 | | | 缩液 | 20233101134 | 2028年8月8日 | | 液透析治疗。 | 一、医疗器械注册证的主要内容 二、对公司的影响 公司本次获得医疗器械注册证的血液透析浓缩液由 A 液和 B 液组成。A 液由氯 化钠、氯化钾、氯化钙、氯化镁和冰醋酸组成，B 液由碳酸氢钠组成。 低钙血症是慢性肾衰竭患者特别是透析患者最常见的并发症之一。本次 ...

证券代码：300453 证券简称：三鑫医疗 江西三鑫医疗科技股份有限公司 投资者关系活动记录表 编号：20230809 | --- | --- | --- | |----------------|--------------|--------------------------------------| | | 特定对象调研 | 分析师会议 | | | □媒体采访 | 业绩说明会 | | 投资者关系活动 | □新闻发布会 | 路演活动 | | 类别 | 现场参观 | 其他 2023 年半年度业绩交流会（电话会 | 议） 华创证券 西南证券 东吴证券 华安证券 国盛证券 国信证券 国元证券 兴业基金 光大证券 国联证券 国金资管 天弘基金 中意资产 AZIMUT（安中） 淡水泉投资 万和弘远 金之灏 金元顺安 泰康资产 易米基金 敦和资管 野村资管 正圆投资 明河投资 源峰基金 湘财基金 阿尔法 沣谊投资 明世伙伴 格林基金 信达澳亚 泰信基金 富安达 和谐汇一 环懿基金 鹤禧投资 优益增 安信资管 中天国富 生命保险 东证衍生品 国华兴益 参与单位名称 南方基金 世纪证券 建信基金 汇添富 恒立基金 建信养老 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, achieving a total of RMB 500 million, representing a growth of 15% compared to the same period in 2022[23]. - The company's operating revenue for the reporting period was ¥581,745,548.36, a decrease of 11.88% compared to ¥660,203,926.41 in the same period last year[29]. - The net profit attributable to shareholders was ¥89,479,881.40, down 14.57% from ¥104,736,931.56 year-on-year[29]. - The net profit after deducting non-recurring gains and losses was ¥78,449,998.15, reflecting a decline of 20.35% compared to ¥98,496,899.72 in the previous year[29]. - The net cash flow from operating activities increased by 12.48% to ¥98,210,338.19 from ¥87,312,813.69 in the same period last year[29]. - The company will not distribute cash dividends or issue bonus shares for the current fiscal year, opting to reinvest profits into growth initiatives[11]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, targeting a 25% increase in market share within the domestic medical device sector by the end of 2024[9]. - The company has set a revenue guidance for the second half of 2023, projecting an increase of 10% to 15% over the first half figures[5]. - The company is focusing on enhancing its core competitive advantages through continuous product development and improving service quality[46]. - The company aims to become a leading manufacturer in the blood purification industry and is expanding into early and mid-stage kidney disease interventions[46]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, with a budget of RMB 100 million earmarked for this purpose[9]. Product Development and Innovation - New product development includes the launch of a next-generation blood purification device, expected to enhance treatment efficiency by 30%[10]. - The company has allocated RMB 50 million for research and development in new technologies, focusing on innovative medical devices[10]. - The company has launched new products including a disposable dialysis catheter, which is the first domestically produced variety in its category, enhancing its competitive edge[38]. - The company has developed a complete product chain for blood dialysis, including key technologies that are internationally advanced[49]. - The company has developed new products focusing on safety performance, including needle-free injectors and precision-filtering infusion devices, enhancing safety and user experience in clinical settings[67]. Research and Development - The company has over 30 ongoing research projects, with more than 10 projects specifically focused on vascular intervention products[38]. - The company reported a research and development investment of 33.34 million yuan, accounting for 5.73% of the revenue during the reporting period, with a year-on-year growth of 12.84%[114]. - As of the end of the reporting period, the company had 122 authorized patents and 71 pending patents, with 91 medical device product registration certificates held[114]. - The company has established several research platforms to drive innovation in medical devices[57]. - The company has established a collaborative R&D model with universities and research institutions to drive innovation in blood purification and other medical technologies[103]. Competitive Landscape - The competitive landscape in the blood purification market remains challenging, with foreign companies holding a significant market share, necessitating strategic pricing adjustments[9]. - The blood dialysis machine market in China is dominated by imports, accounting for 80%-90% of the market share, while domestic brands hold only 10%-20%[56]. - The domestic blood purification market is highly competitive, with significant pressure on pricing due to centralized procurement policies[146]. - The company is addressing the impact of medical device procurement policies on product pricing and market competition[149]. Social Responsibility and Community Engagement - The company has been recognized as a "Leading Enterprise in Social Responsibility" by the Jiangxi Provincial Federation of Industry and Commerce in 2022[165]. - The company donated 1 million yuan to the Nanchang University First Affiliated Hospital for kidney transplant assistance, aimed at alleviating the financial burden on economically disadvantaged kidney disease patients[166]. - The company organized the "2023 Sanxin Medical Kidney Friends Exchange Conference" to enhance communication among kidney disease patients, healthcare professionals, and the company, focusing on improving product quality and patient care[166]. - The company emphasized its commitment to social responsibility and public welfare, aiming to contribute to a healthier and happier society[166]. Regulatory and Compliance - The company has been recognized as a "National Intellectual Property Advantage Enterprise" by the National Intellectual Property Administration[121]. - The company has participated in the formulation and revision of 2 national standards and 4 industry standards related to infusion products, enhancing its industry position and market competitiveness[69]. - The company has established a comprehensive environmental management system to enhance pollution control and ensure compliance with emission standards[161]. - The company has been recognized as a "standardization work advanced unit" for two consecutive years by the National Medical Extracorporeal Circulation Equipment Standardization Technical Committee[120]. Future Outlook - The global medical device market is projected to grow from $405 billion in 2017 to $699 billion by 2025, with a CAGR of 7.0%[42]. - The company aims to enhance the quality of life for dialysis patients through continuous product development and innovation in the blood purification field[38]. - The company is committed to continuous innovation in infusion product materials and designs, focusing on safety and comfort for patients[68]. - The company is increasing its research and innovation efforts to address clinical treatment challenges faced by dialysis patients[166].

Financial Performance - The company's operating revenue for Q1 2023 was ¥272,919,002.98, a decrease of 15.11% compared to ¥321,497,637.25 in the same period last year[4] - The net profit attributable to shareholders was ¥44,785,584.88, down 5.61% from ¥47,447,455.87 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥36,384,675.79, a decline of 22.21% compared to ¥46,771,607.79 in the previous year[4] - The company reported a total profit of CNY 55,017,634.32 for Q1 2023, down 3.8% from CNY 57,334,356.70 in the same quarter last year[20] - Net profit for Q1 2023 was CNY 47,667,602.73, a decline of 5.4% from CNY 50,359,581.15 in Q1 2022[20] - Earnings per share for Q1 2023 were CNY 0.1127, compared to CNY 0.1204 in Q1 2022, reflecting a decrease of 5.7%[20] Cash Flow - The net cash flow from operating activities was -¥34,889,965.06, a significant decrease of 334.65% from ¥14,868,783.06 in the same period last year[4] - Cash inflow from investment activities totaled 25,221,763.58, down from 41,305,600.49, reflecting reduced investment returns[24] - The net cash flow from financing activities increased to 60,845,893.26, compared to 35,765,877.19 in the prior period, showing improved financing capabilities[24] - Cash received from sales of goods and services was 267,165,289.80, down from 332,918,108.44, reflecting a decline in revenue generation[23] - Cash paid for purchasing goods and services was 201,696,949.97, slightly decreased from 205,756,253.81, indicating stable cost management[23] - Cash inflow from other operating activities was 26,006,178.31, an increase from 17,596,721.84, suggesting improved operational efficiency[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,784,933,256.98, a slight decrease of 0.09% from ¥1,786,535,673.29 at the end of the previous year[4] - The equity attributable to shareholders increased by 4.44% to ¥1,123,946,838.23 from ¥1,076,120,829.73 at the end of the previous year[4] - The company's total liabilities as of Q1 2023 amounted to CNY 587,264,070.27, down from CNY 631,130,435.41 in the previous year[19] - Total current assets decreased from ¥689,282,923.80 at the beginning of the year to ¥662,626,342.45 at the end of the period, representing a decline of approximately 3.5%[15] - Total non-current assets increased from ¥1,097,252,749.49 to ¥1,122,306,914.53, showing an increase of approximately 2.3%[16] - Accounts payable decreased from ¥149,663,372.50 to ¥103,996,608.34, a reduction of about 30.5%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,596, with the largest shareholder holding 24.73% of the shares[10] Other Income and Expenses - Other income increased by 204.66% to ¥8,511,533.70, primarily due to an increase in government subsidies received[9] - Investment income rose significantly by 456.05% to ¥1,069,361.58, attributed to increased financial investment returns[9] - Research and development expenses for Q1 2023 were CNY 7,483,945.25, a decrease of 21.1% from CNY 9,481,656.95 in Q1 2022[19] Operational Insights - The company continues to focus on market expansion and new product development strategies to enhance future growth prospects[19] - The company’s first-quarter report was not audited, which may affect the reliability of the financial data presented[25]

Dividend Distribution - The company plans to distribute a cash dividend of 1.5 RMB per 10 shares and issue 2 bonus shares for every 10 shares held, along with a capital reserve conversion of 1 share for every 10 shares[11]. - The company has maintained a clear and transparent cash dividend policy, ensuring the protection of minority shareholders' rights[174]. - The cash dividend represents 42.86% of the total distributable profit of 524,429,825.50 yuan[175]. - The total cash dividend amount for the 2021 fiscal year was 59,104,125 yuan (including tax), with no stock dividends issued[173]. - The company will also issue 2 bonus shares for every 10 shares held and increase the share capital by 1 share for every 10 shares held, resulting in a total increase of 119,212,410 shares[175]. Financial Performance - The company's operating revenue for 2022 was ¥1,336,002,647.93, representing a 14.75% increase compared to ¥1,164,288,763.57 in 2021[28]. - The net profit attributable to shareholders for 2022 was ¥184,634,263.09, an increase of 18.42% from ¥155,910,663.53 in 2021[28]. - The net cash flow from operating activities increased by 21.98% to ¥402,176,397.74 in 2022, up from ¥329,716,957.18 in 2021[28]. - The total assets at the end of 2022 reached ¥1,786,535,673.29, a 27.06% increase from ¥1,406,039,522.12 at the end of 2021[28]. - The basic earnings per share for 2022 was ¥0.4660, reflecting a 16.56% increase from ¥0.3998 in 2021[28]. Market Overview - The blood purification market is highly competitive, with significant price reductions due to centralized procurement policies, potentially impacting future profitability[10]. - The company is exploring opportunities for market expansion through centralized procurement, which could accelerate the domestic replacement process[10]. - The blood purification market in China increased from ¥9.9 billion in 2017 to ¥13.3 billion in 2021, with an average annual growth rate of 7.66%[54]. - By 2026, the blood purification medical device market in China is expected to reach ¥28 billion, with a CAGR of 16.3%[54]. - The number of end-stage renal disease patients in China rose from 2.5 million in 2017 to 3.6 million in 2021, accounting for over one-third of the global total[51]. Product Development and Innovation - The company is focused on the rapid innovation and iteration of its medical devices, including blood purification and infusion products, to maintain its market leadership[11]. - The company has developed a complete product chain for blood dialysis, including key technologies that are at an internationally advanced level[48]. - The company aims to enhance its market share through innovative products and services, leveraging the ongoing medical infrastructure development in China[44]. - The company has developed China's first three-level reverse osmosis blood dialysis water treatment system, which has been recognized as a major technological equipment[59]. - The company has introduced new products, including a disposable blood dialysis device and a PTA high-pressure balloon dilation catheter, which are expected to enhance its market position[113]. Regulatory and Compliance - The company operates in a heavily regulated industry, with strict requirements for product safety and efficacy[8]. - The company has received multiple certifications for its products, including CE certification for the EU and FDA certification for some products in the US[57]. - The company has participated in the formulation and revision of 2 national standards and 3 industry standards for infusion products, enhancing its competitive position in the market[68]. - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[136]. - The company has enhanced its internal control system in compliance with the latest regulations, ensuring effective governance and decision-making processes[181]. Research and Development - The company’s R&D investment reached ¥66,113,679.40 in 2022, accounting for 4.95% of its operating revenue[111]. - The company holds a total of 111 authorized patents and has 67 patent applications under review as of the end of the reporting period[111]. - The company has been recognized as a "National Intellectual Property Advantage Enterprise" for 2022 by the National Intellectual Property Administration[111]. - The company is currently applying for five medical device registration certificates, with three from the parent company and two from subsidiaries[112]. - The company has developed new infusion devices such as non-DEHP infusion sets and precision filter infusion sets, which have received positive feedback from clinical staff and patients[67]. Corporate Governance - The company has established effective communication channels with shareholders, ensuring their rights to information and decision-making are protected[137]. - The company has implemented a transparent performance evaluation and incentive mechanism for senior management, aligning with legal standards[142]. - The company has maintained independence from its controlling shareholders in terms of business, personnel, assets, and finance, ensuring autonomous operations[144]. - The company has a board of directors consisting of 7 members, including 3 independent directors, all of whom are of Chinese nationality[149]. - The company has a structured salary system based on job evaluation points, education, skills, experience, and company tenure[157]. Social Responsibility and Community Engagement - The company has actively participated in social welfare initiatives, including donations and support for local communities[195]. - The company organized over 300 volunteer service activities during the reporting period to support public health efforts amid ongoing challenges[195]. - The company has been recognized as a "Leading Enterprise in Social Responsibility" by the Jiangxi Provincial Federation of Industry and Commerce in 2022[195]. - The company has committed to fulfilling its tax obligations and maintaining transparency in its operations[194]. - The company has engaged in various community-building activities, fostering a positive work environment and employee morale[194].

Financial Performance - The company's operating revenue for 2022 was ¥1,336,002,647.93, representing a 14.75% increase from ¥1,164,288,763.57 in 2021[28]. - The net profit attributable to shareholders for 2022 was ¥184,634,263.09, an increase of 18.42% compared to ¥155,910,663.53 in 2021[28]. - The net cash flow from operating activities reached ¥402,176,397.74, up 21.98% from ¥329,716,957.18 in the previous year[28]. - The total assets at the end of 2022 amounted to ¥1,786,535,673.29, a 27.06% increase from ¥1,406,039,522.12 at the end of 2021[28]. - The basic earnings per share for 2022 was ¥0.4660, reflecting a 16.56% increase from ¥0.3998 in 2021[28]. - The weighted average return on equity for 2022 was 18.96%, slightly up from 18.64% in 2021[28]. - The company reported a net profit of ¥166,627,610.36 after deducting non-recurring gains and losses, which is a 14.77% increase from ¥145,190,265.25 in 2021[28]. - The company received government subsidies amounting to ¥23,744,029.94 in 2022, compared to ¥17,898,922.83 in 2021[33]. - The company achieved operating revenue of 1,336.00 million yuan, a year-on-year increase of 14.75%[94]. - Net profit attributable to shareholders reached 184.63 million yuan, up 18.42% compared to the previous year[94]. - Blood purification products generated revenue of 882.12 million yuan, representing a growth of 19.91% and accounting for 66.03% of total revenue[94]. Market Position and Competition - The company operates in a highly competitive blood purification market, with significant price reductions due to centralized procurement policies, potentially impacting future profitability[10]. - The company is focused on the rapid innovation and iteration of its medical devices, including blood purification and infusion products, to maintain its market leadership[11]. - The company is committed to expanding its market share through successful bids in centralized procurement processes, which can lead to significant market share gains[10]. - The company has achieved a market share of approximately 10%-20% for domestic blood dialysis machines, while imported machines dominate the market with an 80%-90% share[56]. - The company is a leading player in the blood purification industry, having established a complete product chain for blood dialysis equipment and consumables, with a strong brand influence in the market[57]. - The company has established a global marketing system, with products and services sold in over 60 countries and regions[91]. Product Development and Innovation - The company emphasizes the importance of maintaining strict quality control measures, as its main products are classified as Class III medical devices, which are subject to rigorous regulatory scrutiny[9]. - The company has developed a complete product chain for blood dialysis, including key technologies that are at an internationally advanced level[48]. - The company has completed the full industrial chain layout for blood dialysis consumables, ensuring a solid foundation for rapid revenue growth over the past decade[60]. - The company has added new medical devices, including a disposable blood dialysis device and a PTA high-pressure balloon dilation catheter, enhancing its product portfolio[113]. - The company has developed a range of infusion products, including safety injection devices and precision filtration infusion systems, to meet diverse patient needs[67]. - The company’s PTA high-pressure balloon catheter has achieved industry-leading performance indicators, enhancing its competitive edge in the market[64]. - The company has participated in the formulation and revision of 2 national standards and 3 industry standards for infusion products, enhancing its competitive position in the market[68]. Regulatory and Compliance - The company faces risks related to national policy changes that could alter the competitive landscape of the medical device industry[7]. - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[136]. - The company has implemented a transparent performance evaluation and incentive mechanism for senior management, aligning with legal standards[142]. - The company has enhanced its internal control system in compliance with the latest regulations, ensuring effective governance and decision-making processes[181]. - The company has established internal and external supervision systems to protect shareholder rights and ensure transparency in decision-making processes[193]. Corporate Social Responsibility - The company has focused on enhancing employee welfare while contributing to the advancement of health initiatives, reflecting its commitment to social responsibility[193]. - The company actively created employment opportunities, absorbing over 1,000 urban and rural residents for job creation, contributing to rural revitalization efforts[196]. - The company organized over 300 volunteer service activities during the reporting period to support public health efforts amid ongoing challenges[195]. - The company has been awarded the title of "Major Taxpayer Enterprise" multiple times, reflecting its commitment to integrity in business operations[198]. - The company was recognized as a "Leading Enterprise in Social Responsibility" by the Jiangxi Provincial Federation of Industry and Commerce in 2022[195]. Research and Development - The company has built a strong R&D foundation, participating in the formulation of 2 national standards and 9 industry standards[94]. - The company’s R&D investment reached ¥66,113,679.40 in 2022, accounting for 4.95% of its operating revenue[111]. - The number of R&D personnel increased to 249 in 2022, representing a growth of 0.81% compared to 2021[111]. - The company holds a total of 111 authorized patents and has 67 patent applications under review as of the end of the reporting period[111]. - The company aims to enhance its core competitiveness through the implementation of new product projects, including needle-free injection systems and CRRT tubing[110]. Shareholder Engagement and Governance - The annual shareholders' meeting had a participation rate of 30.58% in April 2022, reflecting shareholder engagement[145]. - The first extraordinary shareholders' meeting in June 2022 had a participation rate of 30.57%, indicating continued shareholder involvement[145]. - The company has established effective communication channels with shareholders, ensuring their rights to information and decision-making are protected[137]. - The company has not experienced any violations by controlling shareholders regarding the appropriation of company funds or assets during the reporting period[140]. - The company has a structured salary system based on job evaluation points, education, skills, experience, and tenure[157]. Environmental Responsibility - The company has implemented measures to reduce carbon emissions, including the use of advanced production processes and lightweight materials, contributing to energy savings[190]. - The company has a comprehensive environmental management system in place to ensure compliance with pollution discharge standards and promote clean production practices[190]. - The company has not reported any significant environmental penalties during the reporting period, indicating compliance with environmental regulations[188].

证券代码：300453 证券简称：三鑫医疗 公告编号：2023-021 江西三鑫医疗科技股份有限公司 关于举行2022年度业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"）已于2023年3月23日在巨 潮资讯网（http://www.cninfo.com.cn/）上披露了《<2022年年度报告全文>及其摘 要》。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年3月31 日（星期五）下午15：00至17：00举行2022年度网上业绩说明会。本次年度业绩说 明会将通过深圳证券交易所提供的"互动易"平台和深圳价值在线信息科技股份有 限公司提供的"价值在线"平台采用网络远程的方式同步举行。 参与方式一：通过深圳证券交易所提供的"互动易"平台举行，投资者可登陆 "互动易"网站（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次业 绩说明会。 参与方式二：投资者可于2023年3月31日（星期五）下午15:00-17:00通过网址 https://eseb.cn/ ...

Group 1: Impact of COVID-19 and Business Performance - The pandemic has had a certain impact on the company's operations, but the first quarter report shows stable growth, indicating that annual growth remains promising [2][3]. - The company expects a net profit growth of over 100% for Q1 2020 compared to the same period last year [5]. Group 2: Market and Product Development - The company has received over 10 million orders for masks, primarily exporting to Europe [3]. - The company is focusing on expanding its market share in blood purification products, which have shown continuous revenue growth [3][4]. - The company has developed a dialysis tube with an annual production capacity of nearly 20 million sets, significantly exceeding the import ratio [5]. Group 3: Strategic Initiatives and Future Plans - The company actively participates in volume-based procurement, which has increased product sales and market share without significantly affecting factory prices [4]. - The company plans to continue expanding production capacity for blood purification products as the market grows [3][4]. - The company is open to refinancing based on operational needs and is committed to mergers and acquisitions to strengthen its position in the blood purification industry [4][8]. Group 4: Research and Development - The company has made significant breakthroughs in the research of hollow fiber dialysis membrane materials, reducing reliance on foreign technology [6]. - The company invests heavily in R&D to support sustainable growth in the medical device sector, despite the long development cycles [7]. Group 5: Market Position and Competition - The company’s products have received CE certification for entry into the EU market, and it has established a mature overseas sales network, exporting to Europe, Southeast Asia, Africa, and South America [7]. - The company does not see direct competition with certain other brands in the dialysis field, as their products serve different medical needs [5][7].

江西三鑫医疗科技股份有限公司 2022 年第三季度报告 证券代码：300453 证券简称：三鑫医疗 公告编号：2022-052 江西三鑫医疗科技股份有限公司 2022年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季 度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 324,351,752.18 | 2.17% | 984,555,678.59 | 19.13% | ...